Kiriyama S, Hayakawa T, Kondo T, Shibata T, Kitagawa M, Ono H, Sakai Y
2nd Department of Internal Medicine, Nagoya University School of Medicine, Japan.
Cancer. 1990 Apr 1;65(7):1557-61. doi: 10.1002/1097-0142(19900401)65:7<1557::aid-cncr2820650718>3.0.co;2-w.
Levels of serum Span-1, a new tumor marker for pancreatic cancer, were assayed in 64 patients with pancreatic cancer, 90 with nonpancreatic cancer, and 254 with nonmalignancies, involving 55 healthy controls. Furthermore, Span-1 was compared with other tumor markers (CA19-9, carcinoembryonic antigen [CEA], and DU-PAN-2). Frequency of elevated Span-1 levels was 81.3% in pancreatic cancer. False-positive elevations of serum Span-1 levels were rather common in liver cirrhosis (53.8%) and chronic hepatitis (26.3%). The sensitivity, specificity, and efficiency of this assay for pancreatic cancer, was 81.3%, 75.6%, and 76.5% against all subjects without pancreatic cancer, respectively. In comparison with other markers, sensitivity of Span-1 tended to be highest with similar specificity to those of CA19-9 and CEA. The Span-1 assay has a high sensitivity and specificity for pancreatic cancer. It is almost equivalent to CA19-9 assay. However, this assay is not specific for chronic liver diseases.
对64例胰腺癌患者、90例非胰腺癌患者以及254例非恶性疾病患者（包括55例健康对照）检测了血清中一种新的胰腺癌肿瘤标志物Span-1的水平。此外，还将Span-1与其他肿瘤标志物（CA19-9、癌胚抗原[CEA]和DU-PAN-2）进行了比较。胰腺癌患者中Span-1水平升高的频率为81.3%。血清Span-1水平的假阳性升高在肝硬化（53.8%）和慢性肝炎（26.3%）中相当常见。该检测对胰腺癌的敏感性、特异性和效率分别为81.3%、75.6%和76.5%（针对所有无胰腺癌的受试者）。与其他标志物相比，Span-1的敏感性往往最高，特异性与CA19-9和CEA相似。Span-1检测对胰腺癌具有高敏感性和特异性。它几乎等同于CA19-9检测。然而，该检测对慢性肝病不具有特异性。
